布地奈德联合福莫特罗干粉剂在急诊治疗重症支气管哮喘患者中的应用效果评价

目的 观察布地奈德联合福莫特罗干粉剂在急诊治疗重症支气管哮喘患者中的应用效果。方法 参照随机数字表法,将2017年7月—2019年6月在某医院接受急诊治疗的40例重症支气管哮喘患者分为两组,每组各20例。对照组患者采用布地奈德治疗,观察组在对照组基础上联合福莫特罗干粉剂治疗。两组患者均治疗1个月,观察两组C反应蛋白(CRP)、血常规水平及肺功能指标第1秒用力呼气容积(FEV1)、FEV1与用力肺活量(FCV)比值(FEV1/FCV)和最大呼气流量(PEF)]。结果 治疗期间对照组患者夜间睡眠时憋醒次数为(13.55±3.25)次,观察组患者夜间睡眠时憋醒次数为(5.25±0.95)次;组间相比,差异有统计学意义(t=10.962,P<0.05);治疗后,观察组CRP、白细胞计数、嗜酸性粒细胞比率、淋巴细胞比率分别为:(12.36±1.43)mg/L、(6.31±1.05)×109/L、(4.82±2.03)%、(20.06±2.48)%,均低于对照组的(15.98±1.95)mg/L、(8.59±1.34)×109/L、(6.79±2.68)%、(25.09±3.12)%,(t值分别为6.695、5.990、2.621、5.644,P值均<0.05);治疗后,观察组FEV1、PEF及FEV1/FCV水平分别为:(2.51±0.70)L、(3.28±0.75)L/s、(75.38±8.49)%,均高于对照组(2.02±0.52)L、(2.76±0.66)L/s、(62.63±6.89)%,(t 值分别为2.513、2.328、5.215,P值均<0.05)。结论 布地奈德联合福莫特罗干粉剂在急诊重症支气管哮喘患者的治疗中效果较好,能有效改善CRP及血常规水平,提高肺功能。

Evaluation of effect of budesonide combined with formoterol powder in emergency treatment of patients with severe bronchial asthma

Objective To evaluate the effect of budesonide combined with formoterol powder in the emergency treatment of patients with severe bronchial asthma. Methods From July 2017 to June 2019, with the reference of the random number table method, 40 patients with severe bronchial asthma who received the emergency treatment in a hospital were divided into two groups, with 20 cases in each group. The control group was treated with budesonide, and the observation group was treated with formoterol powder on the basis of control group. Both groups were treated for 1 month, The C reactive protein (CRP), blood routine level, and pulmonary function index were observed and compared between the two groups. Results During the treatment period, the average number of waking times during the night sleep in the control group was (13.55±3.25), more than that in the observation group: (5.25±0.95), and there was a significant difference between two groups (t=10.962, P<0.05). After the treatment, in the observation group, the average levels of CRP, white blood cell count, eosinophil ratio and lymphocyte ratio were as follows:(12.36±1.43) mg/L, (6.31±1.05)×109/L, (4.82±2.03)%, and (20.06±2.48)%, which were lower than those in the control group: (15.98±1.95) mg/L, (8.59±1.34)×109/L, (6.79±2.68)%, and (25.09±3.12)%, and the differences were statistically significant (t=6.695, 5.990, 2.621, 5.644, all P<0.05). After the treatment, the average levels of FEV1, PEF and FEV1/FCV in the observation group were as follows: (2.51±0.70) L, (3.28±0.75) L/s, (75.38±8.49), which were higher than those in the control group: (2.02±0.52) L, (2.76±0.66) L/s, (62.63±6.89)%, and the differences were statistically significant (t=2.513, 2.328, 5.215, all P<0.05). Conclusion Budesonide combined with formoterol dry powder is effective in the treatment of severe bronchial asthma, it can effectively improve CRP, blood routine, and lung function of the patients.